{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:06:36Z","timestamp":1789124796487,"version":"build-2803163510"},"reference-count":173,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.addr.2026.115940","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:33:46Z","timestamp":1785800026000},"page":"115940","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The landscape of genetic medicines for in vivo T cell reprogramming"],"prefix":"10.1016","volume":"238","author":[{"given":"Jens B.","family":"Simonsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor T.","family":"Lemgart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayesh A.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Witzigmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2026.115940_bb0005","doi-asserted-by":"crossref","unstructured":"D.J. Baker, Z. Arany, J.A. Baur, J.A. Epstein, C.H. June, CAR T therapy beyond cancer: the evolution of a living drug, Nature 619 (2023), https:\/\/doi.org\/10.1038\/s41586-023-06243-w.","DOI":"10.1038\/s41586-023-06243-w"},{"key":"10.1016\/j.addr.2026.115940_bb0010","article-title":"CAR-T cell therapy for cancer: current challenges and future directions, Signal Transduct","volume":"10","author":"Zugasti","year":"2025","journal-title":"Target. Ther."},{"key":"10.1016\/j.addr.2026.115940_bb0015","doi-asserted-by":"crossref","DOI":"10.1038\/s42255-022-00537-5","article-title":"CAR-based therapies: opportunities for immuno-medicine beyond cancer","author":"Aghajanian","year":"2022","journal-title":"Nat. Metab."},{"key":"10.1016\/j.addr.2026.115940_bb0020","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-023-00534-0","article-title":"Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges","author":"Pang","year":"2023","journal-title":"Biomark. Res."},{"key":"10.1016\/j.addr.2026.115940_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.835762","article-title":"Cancer therapy with TCR-engineered T cells: current strategies, challenges, and prospects","author":"Shafer","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2026.115940_bb0030","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ado2084","article-title":"Engineering CAR-T therapies for autoimmune disease and beyond","volume":"16","author":"English","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2026.115940_bb0035","article-title":"In vivo chimeric antigen receptor (CAR)-T cell therapy","author":"Bot","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2026.115940_bb0040","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2026.115940_bb0045","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-022-02017-5","article-title":"Author correction: Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus (Nature Medicine, (2022), 28, 10, (2124\u20132132), 10.1038\/s41591-022-02017-5)","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2026.115940_bb0050","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-180547","article-title":"CD19-targeted CAR-T cells in refractory systemic autoimmune diseases: a monocentric experience from the first fifteen patients","volume":"142","author":"Mueller","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.addr.2026.115940_bb0055","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.addr.2026.115940_bb0060","article-title":"Author correction: decade-long leukaemia remissions with persistence of CD4+ CAR T cells (Nature, (2022), 602, 7897, (503\u2013509), 10.1038\/s41586-021-04390-6)","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.addr.2026.115940_bb0065","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.addr.2026.115940_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/cells9051225","article-title":"Current challenges in providing good leukapheresis products for manufacturing of CAR-T cells for patients with relapsed\/refractory NHL or ALL","author":"Korell","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.addr.2026.115940_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106742","article-title":"Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: a definite evidence from systematic review and meta-analysis on individual data","author":"Zinzi","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.addr.2026.115940_bb0080","series-title":"Janeway's Immunobiology","article-title":"Janeway's immunobiology","author":"Murphy","year":"2016"},{"key":"10.1016\/j.addr.2026.115940_bb0085","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2308511120","article-title":"The total mass, number, and distribution of immune cells in the human body","volume":"120","author":"Sender","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2026.115940_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.it.2005.04.011","article-title":"The bone marrow: a nest for migratory memory T cells","author":"Di Rosa","year":"2005","journal-title":"Trends Immunol."},{"key":"10.1016\/j.addr.2026.115940_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006624","article-title":"Imbalance in the game of T cells: what can the CD4\/CD8 T-cell ratio tell us about HIV and health","author":"McBride","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.addr.2026.115940_bb0125","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2362.2006.01626.x","article-title":"T-lymphocyte subset distribution in human spleen","author":"Langeveld","year":"2006","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.addr.2026.115940_bb0130","doi-asserted-by":"crossref","DOI":"10.1111\/j.1749-6632.1993.tb38799.x","article-title":"Clinical utility of a lymph node normal range obtained by flow cytometry","author":"Bryan","year":"1993","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.addr.2026.115940_bb0135","doi-asserted-by":"crossref","DOI":"10.1007\/s12308-021-00472-6","article-title":"Characterization of bone marrow CD4 to CD8 ratios and lymphocyte composition in adults by image analysis","author":"Adkins","year":"2021","journal-title":"J. Hematop."},{"key":"10.1016\/j.addr.2026.115940_bb0140","doi-asserted-by":"crossref","DOI":"10.1136\/jcp.47.6.505","article-title":"Bone marrow lymphocyte subsets in myelodysplastic syndromes","author":"Hilbe","year":"1994","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.addr.2026.115940_bb0145","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V99.2.561","article-title":"Quantitative trait loci regulating relative lymphocyte proportions in mouse peripheral blood","author":"Chen","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.addr.2026.115940_bb0150","doi-asserted-by":"crossref","DOI":"10.1186\/s12979-021-00214-3","article-title":"Sex- and age-dependent alterations of splenic immune cell profile and NK cell phenotypes and function in C57BL\/6J mice","author":"Menees","year":"2021","journal-title":"Immun. Ageing"},{"key":"10.1016\/j.addr.2026.115940_bb0155","doi-asserted-by":"crossref","DOI":"10.1038\/s41374-018-0137-1","article-title":"Characterization of immune cell subtypes in three commonly used mouse strains reveals gender and strain-specific variations","author":"Hensel","year":"2019","journal-title":"Lab. Invest."},{"key":"10.1016\/j.addr.2026.115940_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2018.01.007","article-title":"Human T cell development, localization, and function throughout life","author":"Kumar","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.addr.2026.115940_bb0095","article-title":"Higher doses of CAR-T therapy bring survival advantage for B-ALL patients","year":"2022","journal-title":"Oncol. Times"},{"key":"10.1016\/j.addr.2026.115940_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.886637","article-title":"Influence of culture conditions on ex vivo expansion of T lymphocytes and their function for therapy: current insights and open questions","author":"Sudarsanam","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.addr.2026.115940_bb0110","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"80","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.addr.2026.115940_bb0115","article-title":"1203 targeted in vivo generation of CAR T and NK cells utilizing an engineered lentiviral vector platform","author":"Andorko","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.addr.2026.115940_bb0160","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.0709713105","article-title":"Sparse production but preferential incorporation of recently produced na\u00efve T cells in the human peripheral pool","author":"Vrisekoop","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2026.115940_bb0165","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2013-03-488411","article-title":"Closing the gap between T-cell life span estimates from stable isotope-labeling studies in mice and humans","author":"Westera","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.addr.2026.115940_bb0170","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1182\/blood-2017-08-752121","article-title":"Posttransplant chimeric antigen receptor therapy","volume":"131","author":"Smith","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.addr.2026.115940_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21113906","article-title":"CAR-T cell therapies: an overview of clinical studies supporting their approved use against acute lymphoblastic leukemia and large b-cell lymphomas","author":"Ahmad","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2026.115940_bb0180","doi-asserted-by":"crossref","DOI":"10.1159\/000496870","article-title":"Chimeric antigen receptor T cells: a race to revolutionize cancer therapy","author":"Subklewe","year":"2019","journal-title":"Transfus. Med. Hemother."},{"key":"10.1016\/j.addr.2026.115940_bb0185","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115940_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2026.115940_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2026.115940_bb0200","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115940_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2009.02.009","article-title":"The promise and potential pitfalls of chimeric antigen receptors","author":"Sadelain","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.addr.2026.115940_bb0210","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.addr.2026.115940_bb0215","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2010.026310","article-title":"Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors","author":"Marin","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.addr.2026.115940_bb0220","doi-asserted-by":"crossref","DOI":"10.1002\/acg2.84","article-title":"TRUCKS, the fourth-generation CAR T cells: current developments and clinical translation","author":"Chmielewski","year":"2020","journal-title":"Adv. Cell Gene Ther."},{"key":"10.1016\/j.addr.2026.115940_bb0225","doi-asserted-by":"crossref","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects","author":"Kagoya","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2026.115940_bb0230","doi-asserted-by":"crossref","DOI":"10.3390\/biom10020263","article-title":"Recent advances in allogeneic CAR-T cells","author":"Kim","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.addr.2026.115940_bb0235","article-title":"Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments","author":"Dagar","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.addr.2026.115940_bb0240","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","author":"Mitra","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2026.115940_bb0245","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.addr.2026.115940_bb0250","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-018-0116-0","article-title":"Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy","author":"Wang","year":"2018","journal-title":"Biomark. Res."},{"key":"10.1016\/j.addr.2026.115940_bb0255","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115940_bb0260","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115940_bb0265","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade letter","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2026.115940_bb0270","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-018-0653-x","article-title":"Cytokine release syndrome: grading, modeling, and new therapy","author":"Liu","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.addr.2026.115940_bb0275","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","author":"Le","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.addr.2026.115940_bb0280","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.addr.2026.115940_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.03.006","article-title":"Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a systematic review","author":"Grant","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.addr.2026.115940_bb0290","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-020-01134-4","article-title":"Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL","author":"Sheth","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.addr.2026.115940_bb0295","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-023-02767-w","article-title":"Unanswered questions following reports of secondary malignancies after CAR-T cell therapy","author":"Levine","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2026.115940_bb0300","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1165870","article-title":"Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL","author":"Aparicio-P\u00e9rez","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2026.115940_bb0305","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02664","article-title":"Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies","author":"Xu","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2026.115940_bb0310","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.886546","article-title":"Immunogenicity of CAR-T cell therapeutics: evidence, mechanism and mitigation","author":"Khan","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2026.115940_bb0315","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-022-03442-3","article-title":"Exhaustion of CAR T cells: potential causes and solutions","author":"Kouro","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.addr.2026.115940_bb0320","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0549-5","article-title":"Lymphopenia in cancer patients and its effects on response to immunotherapy: an opportunity for combination with cytokines?","author":"M\u00e9n\u00e9trier-Caux","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.addr.2026.115940_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105266","article-title":"Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment","volume":"106","author":"Bui","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.addr.2026.115940_bb0330","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-020-0956-8","article-title":"Value and affordability of CAR T-cell therapy in the United States","author":"Fiorenza","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.addr.2026.115940_bb0335","article-title":"Price and prejudice? The value of chimeric antigen receptor (CAR) T-cell therapy","author":"Choi","year":"2022","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.addr.2026.115940_bb0340","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.809754","article-title":"In-vivo induced CAR-T cell for the potential breakthrough to overcome the barriers of current CAR-T cell therapy","author":"Xin","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.addr.2026.115940_bb0345","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004185","article-title":"To go or not to go? Biological logic gating engineered T cells","author":"Abbott","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.addr.2026.115940_bb0350","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","author":"Spiegel","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2026.115940_bb0355","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.618427","article-title":"Allogeneic CAR cell therapy\u2014more than a pipe dream","author":"Caldwell","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2026.115940_bb0360","doi-asserted-by":"crossref","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2026.115940_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","author":"Granit","year":"2023","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.addr.2026.115940_bb0370","article-title":"Correction to Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","year":"2023","journal-title":"S1. The Lancet Neurology"},{"key":"10.1016\/j.addr.2026.115940_bb0375","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2508023","article-title":"CD19 CAR T-cell therapy in multidrug-resistant ulcerative colitis","volume":"393","author":"M\u00fcller","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115940_bb0380","doi-asserted-by":"crossref","DOI":"10.1111\/ajt.14185","article-title":"Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection","author":"Boardman","year":"2017","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.addr.2026.115940_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2017.01.001","article-title":"Generation of human islet-specific regulatory T cells by TCR gene transfer","author":"Hull","year":"2017","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.addr.2026.115940_bb0390","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10020287","article-title":"CAR-T regulatory (CAR-Treg) cells: engineering and applications","author":"Arjomandnejad","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.addr.2026.115940_bb0395","doi-asserted-by":"crossref","DOI":"10.1038\/s41576-021-00329-9","article-title":"Genetic engineering of T cells for immunotherapy","author":"Ellis","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.addr.2026.115940_bb0400","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf3700","article-title":"TCR-engineered T cell therapy in solid tumors: state of the art and perspectives","author":"Baulu","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.addr.2026.115940_bb0405","article-title":"Tumor infiltrating lymphocyte (TIL) therapy for solid tumor treatment: progressions and challenges","author":"Zhao","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.addr.2026.115940_bb0410","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-bioeng-070620-033348","article-title":"In situ programming of CAR T cells","author":"Parayath","year":"2021","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"10.1016\/j.addr.2026.115940_bb0415","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.addr.2026.115940_bb0455","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00508-1","article-title":"AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia","author":"Nawaz","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.addr.2026.115940_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2020.05.005","article-title":"In vivo generation of CAR T cells selectively in human CD4+ lymphocytes","author":"Agarwal","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2026.115940_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2021.06.004","article-title":"Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs","author":"Tomb\u00e1cz","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2026.115940_bb0515","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1671761","article-title":"In vivo generated human CAR T cells eradicate tumor cells","author":"Agarwal","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.addr.2026.115940_bb0520","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809158","article-title":"In vivo generation of human CD 19- CAR T cells results in B-cell depletion and signs of cytokine release syndrome","author":"Pfeiffer","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.addr.2026.115940_bb0525","article-title":"Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors","author":"Frank","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.addr.2026.115940_bb0445","doi-asserted-by":"crossref","DOI":"10.1038\/nnano.2017.57","article-title":"In situ programming of leukaemia-specific t cells using synthetic DNA nanocarriers","author":"Smith","year":"2017","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2026.115940_bb0450","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-19486-2","article-title":"In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo","author":"Parayath","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115940_bb0475","doi-asserted-by":"crossref","DOI":"10.1021\/acsnano.5b02796","article-title":"Systemic gene silencing in primary T lymphocytes using targeted lipid nanoparticles","author":"Ramishetti","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115940_bb0485","article-title":"Spleen SORT LNP generated in situ CAR T cells extend survival in a mouse model of lymphoreplete B cell lymphoma","author":"\u00c1lvarez-Benedicto","year":"2023","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.addr.2026.115940_bb0495","article-title":"In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism","author":"Billingsley","year":"2023","journal-title":"Small"},{"key":"10.1016\/j.addr.2026.115940_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121339","article-title":"In situ T-cell transfection by anti-CD3-conjugated lipid nanoparticles leads to T-cell activation, migration, and phenotypic shift","author":"Kheirolomoom","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2026.115940_bb0535","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006292","article-title":"Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering","author":"Michels","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.addr.2026.115940_bb0540","doi-asserted-by":"crossref","DOI":"10.1038\/s41587-023-02085-z","article-title":"In vivo human T cell engineering with enveloped delivery vehicles","author":"Hamilton","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2026.115940_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114416","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","author":"Hald Albertsen","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2026.115940_bb0425","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-13880-1","article-title":"Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy","author":"Sheih","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115940_bb0430","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-024-07762-w","article-title":"Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission","author":"Bai","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.addr.2026.115940_bb0435","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2040772","article-title":"Single-cell analysis by mass cytometry reveals CD19 CAR T cell spatiotemporal plasticity in patients","author":"Goldberg","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.addr.2026.115940_bb0440","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-023-01908-x","article-title":"Spatial single cell analysis of tumor microenvironment remodeling pattern in primary central nervous system lymphoma","author":"Xia","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.addr.2026.115940_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101139","article-title":"Lipid nanoparticles outperform electroporation in mRNA-based CAR T cell engineering","volume":"31","author":"Kitte","year":"2023","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"key":"10.1016\/j.addr.2026.115940_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2015.08.007","article-title":"Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes","author":"Pardi","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115940_bb0480","article-title":"Exclusive transduction of human CD4+ T cells upon systemic delivery of CD4-targeted lentiviral vectors","author":"Zhou","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2026.115940_bb0490","doi-asserted-by":"crossref","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2026.115940_bb0500","doi-asserted-by":"crossref","DOI":"10.1038\/s41596-025-01330-w","article-title":"Preparation of targeted lipid nanoparticles for precision nucleic acid delivery","author":"Geisler","year":"2026","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.addr.2026.115940_bb0530","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2013-11-540641","article-title":"Mystery solved: VSV-G-LVs do not allow efficient gene transfer into unstimulated T cells, B cells, and HSCs because they lack the LDL receptor","author":"Amirache","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.addr.2026.115940_bb0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2022.06.004","article-title":"In vivo generation of CAR T cells in the presence of human myeloid cells","author":"Ho","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.addr.2026.115940_bb0555","doi-asserted-by":"crossref","DOI":"10.3791\/54048","article-title":"Stem-cell based engineered immunity against HIV infection in the humanized mouse model","author":"Zhen","year":"2016","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.addr.2026.115940_bb0550","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-11321-7","article-title":"Standard screening methods underreport AAV-mediated transduction and gene editing","author":"Lang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115940_bb0560","doi-asserted-by":"crossref","DOI":"10.1098\/rsif.2020.1013","article-title":"Quantifying the limits of CAR T-cell delivery in mice and men","author":"Brown","year":"2021","journal-title":"J. R. Soc. Interface"},{"key":"10.1016\/j.addr.2026.115940_bb0565","article-title":"Tisagenlecleucel model-based cellular kinetic analysis of chimeric antigen receptor\u2013T cells","author":"Stein","year":"2019","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"key":"10.1016\/j.addr.2026.115940_bb0570","doi-asserted-by":"crossref","unstructured":"Maurice Morillon, Y., Sabzevari, A., Schlom, J. & Greiner, J. W. The development of next-generation PBMC humanized mice for preclinical investigation of cancer immunotherapeutic agents. Anticancer Res. (2020) doi:10.21873\/anticanres.14540.","DOI":"10.21873\/anticanres.14540"},{"key":"10.1016\/j.addr.2026.115940_bb0575","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-022-00721-2","article-title":"Humanized mouse models for immuno-oncology research","author":"Chuprin","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.addr.2026.115940_bb0580","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-pathol-052016-100332","article-title":"Humanized mouse models of clinical disease","author":"Walsh","year":"2017","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.addr.2026.115940_bb0590","doi-asserted-by":"crossref","DOI":"10.1007\/s13238-021-00821-2","article-title":"Potentiating CD8+ T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling","author":"Yuan","year":"2021","journal-title":"Protein Cell"},{"key":"10.1016\/j.addr.2026.115940_bb0595","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2319856121","article-title":"IL7 increases targeted lipid nanoparticle\u2013mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translation","volume":"121","author":"Tilsed","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2026.115940_bb0600","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01664","article-title":"Cholesterol metabolism in T cells","author":"Bietz","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2026.115940_bb0605","article-title":"Low level of high-density lipoprotein cholesterol correlates with poor prognosis in extranodal natural killer\/T cell lymphoma","author":"Wang","year":"2014","journal-title":"Tumor Biol."},{"key":"10.1016\/j.addr.2026.115940_bb0610","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCRESAHA.116.310054","article-title":"Hypercholesterolemia induces differentiation of regulatory T cells in the liver","author":"Mailer","year":"2017","journal-title":"Circ. Res."},{"key":"10.1016\/j.addr.2026.115940_bb0615","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.11462","article-title":"Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma","author":"Tagawa","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.addr.2026.115940_bb0620","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.21669","article-title":"Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100","author":"Spaner","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.addr.2026.115940_bb0625","doi-asserted-by":"crossref","DOI":"10.1038\/mt.2009.275","article-title":"Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma","author":"Adamina","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2026.115940_bb0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2020.07.023","article-title":"Cell and tissue engineering in lymph nodes for cancer immunotherapy","author":"Najibi","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2026.115940_bb0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2017.03.033","article-title":"Synthetic nanovaccines for immunotherapy","author":"Luo","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115940_bb0640","doi-asserted-by":"crossref","DOI":"10.1002\/eji.200737984","article-title":"Nanoparticles target distinct dendritic cell populations according to their size","author":"Manolova","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.addr.2026.115940_bb0645","doi-asserted-by":"crossref","DOI":"10.1038\/s41578-019-0110-7","article-title":"Material design for lymph node drug delivery","author":"Schudel","year":"2019","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.addr.2026.115940_bb0650","doi-asserted-by":"crossref","DOI":"10.2147\/IJN.S212037","article-title":"Top-down fabrication-based nano\/microparticles for molecular imaging and drug delivery","author":"Aryal","year":"2019","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2026.115940_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2022.03.046","article-title":"The replacement of helper lipids with charged alternatives in lipid nanoparticles facilitates targeted mRNA delivery to the spleen and lungs","author":"LoPresti","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115940_bb0660","doi-asserted-by":"crossref","DOI":"10.7150\/thno.89913","article-title":"Bile acid-containing lipid nanoparticles enhance extrahepatic mRNA delivery","author":"Patel","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.addr.2026.115940_bb0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.omto.2020.07.005","article-title":"Analysis and augmentation of the immunologic bystander effects of CAR T cell therapy in a syngeneic mouse cancer model","author":"Klampatsa","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.addr.2026.115940_bb0670","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor\u2013modified T cells in chronic lymphoid leukemia","author":"Porter","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115940_bb0675","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","author":"Fraietta","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2026.115940_bb0680","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-021-00842-6","article-title":"Rapid manufacturing of non-activated potent CAR T cells","author":"Ghassemi","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.addr.2026.115940_bb0685","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-22-1276","article-title":"A novel autologous CAR-T therapy, YTB323, with preserved T-cell stemness shows enhanced CAR T-cell efficacy in preclinical and early clinical development","author":"Dickinson","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.addr.2026.115940_bb0690","article-title":"Viral vector-based gene therapy","author":"Li","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2026.115940_bb0695","article-title":"Viral vector-based gene therapies in the clinic","author":"Zhao","year":"2022","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.addr.2026.115940_bb0700","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115940_bb0705","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115940_bb0710","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115940_bb0715","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","author":"Philipp","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.addr.2026.115940_bb0720","doi-asserted-by":"crossref","DOI":"10.2147\/IJN.S424723","article-title":"Delivery of plasmid DNA by ionizable lipid nanoparticles to induce CAR expression in T cells","volume":"18","author":"Prazeres","year":"2023","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2026.115940_bb0725","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2018.03.029","article-title":"Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial","author":"Beatty","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2026.115940_bb0730","doi-asserted-by":"crossref","DOI":"10.1038\/ncponc0666","article-title":"Increased intensity lymphodepletion and adoptive immunotherapy - how far can we go?","author":"Muranski","year":"2006","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"10.1016\/j.addr.2026.115940_bb0735","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-022-00698-0","article-title":"Immunological barriers to haematopoietic stem cell gene therapy","author":"Charlesworth","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2026.115940_bb0740","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-3565(24)35391-1","article-title":"Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes","author":"Dams","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.addr.2026.115940_bb0745","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-018-0326-x","article-title":"Identification of preexisting adaptive immunity to Cas9 proteins in humans","author":"Charlesworth","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2026.115940_bb0750","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-00481-z","article-title":"Endocytic sorting motif interactions involved in Nef-mediated downmodulation of CD4 and CD3","author":"Manrique","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115940_bb0755","doi-asserted-by":"crossref","DOI":"10.1084\/jem.173.3.575","article-title":"Differential endocytosis of CD4 in lymphocytic and nonlymphocytic cells","author":"Pelchen-Matthews","year":"1991","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.addr.2026.115940_bb0760","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.168.11.5612","article-title":"AP2 adaptor complex-dependent internalization of CD5: differential regulation in T and B cells","author":"Lu","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2026.115940_bb0765","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.158.7.3259","article-title":"Construction and characterization of human CD7-specific single-chain Fv immunotoxins","author":"Pauza","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2026.115940_bb0770","article-title":"Rapid receptor internalization potentiates CD7-targeted lipid nanoparticles for efficient mRNA delivery to T cells and in vivo CAR T-cell engineering","author":"Zeng","year":"2026","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2026.115940_bb0775","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.143.6.1905","article-title":"Comparison of phosphorylation and internalization of the antigen receptor\/CD3 complex, CD8, and class I MHC-encoded proteins on T cells. Role of intracytoplasmic domains analyzed with hybrid CD8\/class I molecules","author":"Boyer","year":"1989","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2026.115940_bb0780","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.42276","article-title":"Optimization-by-design of hepatotropic lipid nanoparticles targeting the sodium-taurocholate cotransporting polypeptide","author":"Witzigmann","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.addr.2026.115940_bb0785","doi-asserted-by":"crossref","DOI":"10.1038\/s41578-022-00529-7","article-title":"Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs","author":"Dilliard","year":"2023","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.addr.2026.115940_bb0790","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2026.02.020","article-title":"Reprogramming CD22 CAR-T cells in vivo using CD8-targeted mRNA-LNPs to treat hematological malignancies","author":"Lemgart","year":"2026","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2026.115940_bb0795","series-title":"ASGCT 28th Annual Meeting Abstracts","author":"Lemgart","year":"2025"},{"key":"10.1016\/j.addr.2026.115940_bb0800","doi-asserted-by":"crossref","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2026.115940_bb0805","doi-asserted-by":"crossref","DOI":"10.1021\/acs.bioconjchem.0c00366","article-title":"The biomolecular corona of lipid nanoparticles for gene therapy","author":"Francia","year":"2020","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2026.115940_bb0810","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2016.05.059","article-title":"Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA","author":"Chen","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115940_bb0815","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2005.09.014","article-title":"Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes","author":"Judge","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2026.115940_bb0820","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-023-00766-z","article-title":"Polyethylene glycol (PEG)-associated immune responses triggered by clinically relevant lipid nanoparticles in rats","author":"Wang","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.addr.2026.115940_bb0825","article-title":"Designing around immune memory to counter PEG immunogenicity","author":"Namit Chaudhary","year":"2025","journal-title":"Nat. Mater."},{"key":"10.1016\/j.addr.2026.115940_bb0830","author":"NanoVation Tx"},{"key":"10.1016\/j.addr.2026.115940_bb0835","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0140-6736(25)01030-X","article-title":"In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma","volume":"406","author":"Xu","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2026.115940_bb0840","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-026-04244-6","article-title":"In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study","author":"An","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2026.115940_bb0845","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2411507","article-title":"CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53","volume":"392","author":"Perica","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115940_bb0850","doi-asserted-by":"crossref","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","author":"Hunter","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.addr.2026.115940_bb0855","unstructured":"Immorna. News Update Immorna Announces First Evidence of Tissue B Cell Depletion with In Vivo CAR T JCXH 213 in Systemic Sclerosis Patient, Underscoring Platform's Potential to Address Autoimmune Diseases. https:\/\/www.immornabio.com\/News-details\/41.html (2026)."},{"key":"10.1016\/j.addr.2026.115940_bb0860","series-title":"LinkedIn post: EsoBioTec\/AstraZeneca\u2019s in-vivo CAR-T therapy shows promising results at ESGCT 2025","author":"Mayr","year":"2025"},{"key":"10.1016\/j.addr.2026.115940_bb0865","article-title":"In vivo reprogramming of cytotoxic effector CD8 T cells via fractalkine-conjugated mRNA-LNPs","author":"Corrigan","year":"2025","journal-title":"Science Immunology"},{"key":"10.1016\/j.addr.2026.115940_bb0870","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2025.06.008","article-title":"The future belongs to those who believe in multiplex CAR T engineering","volume":"32","author":"Volta","year":"2025","journal-title":"Cell Stem Cell"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26001742?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26001742?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:16:03Z","timestamp":1789121763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X26001742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":173,"alternative-id":["S0169409X26001742"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2026.115940","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The landscape of genetic medicines for in vivo T cell reprogramming","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2026.115940","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115940"}}